EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of DYNLT3 in breast cancer proliferation, migration, and invasion via epithelial‐to‐mesenchymal transition

Han Wang, Xin Chen, Yanshan Jin, Tingxian Liu, Yizuo Song, Xuejie Zhu, Xueqiong Zhu iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Han Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

DYNLT3 is identified as an age‐related gene. Nevertheless, the specific mechanism of its carcinogenesis in breast tumor has not been clarified. This research aims to elucidate the role and the underlying molecular pathways of DYNLT3 on breast cancer tumorigenesis.

Methods

The differential expression of DYNLT3 among breast cancer, breast fibroids, and normal tissues, as well as in various breast cancer cell lines were detected by immunohistochemical staining, real‐time quantitative reverse transcription‐PCR and Western blotting, respectively. Additionally, the role of DYNLT3 on cell viability and proliferation were observed through cell counting kit‐8, bromodeoxyuridine, and colony formation experiments. Migratory and invasive abilities was envaulted by wound healing and Transwell methods. Apoptotic cells rate was examined by flow cytometry. Furthermore, nude mice xenograft models were established to confirm the role of DYNLT3 in tumor formation in vivo.

Results

DYNLT3 expression was highly rising in both breast cancer tissues and cells. DYNLT3 knockdown obviously suppressed cell growth, migration and invasion, and induced cell apoptosis in MDA‐MB‐231 and MCF‐7 breast cancer cells. The overexpression of DYNLT3 exerted the opposite effect in MDA‐MB‐231 cells. Moreover, DYNLT3 knockdown inhibited tumor formation in vivo. Mechanistically, an elevation of N‐cadherin and vimentin levels and a decline of E‐cadherin were observed when DYNLT3 was upregulated, which was reversed when DYNLT3 knockdown was performed.

Conclusion

DYNLT3 may function as a tumor‐promotor of age‐associated breast cancer, which is expected to provide experimental basis for new treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAnimalsMiceHumansFemaleCell Line, TumorMice, NudeMCF-7 CellsCell ProliferationCarcinogenesisEpithelial-Mesenchymal TransitionCell MovementGene Expression Regulation, NeoplasticDyneins

Stichwörter der Autor:innen

DYNLT3E-cadherinEMTbreast cancervimentin

Substanzen

DYNLT3 protein, humanDyneinsDYNLT3 protein, mouse

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Xueqiong Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, H., Chen, X., Jin, Y., Liu, T., Song, Y., Zhu, X., & Zhu, X. (2023). The role of DYNLT3 in breast cancer proliferation, migration, and invasion via epithelial‐to‐mesenchymal transition. Cancer Medicine. https://doi.org/10.1002/cam4.6173

Vancouver

Wang H, Chen X, Jin Y, Liu T, Song Y, Zhu X, et al. The role of DYNLT3 in breast cancer proliferation, migration, and invasion via epithelial‐to‐mesenchymal transition. Cancer Medicine. 2023. doi:10.1002/cam4.6173

BibTeX
@article{Wang2023,
  author = {Wang, Han and Chen, Xin and Jin, Yanshan and Liu, Tingxian and Song, Yizuo and Zhu, Xuejie and Zhu, Xueqiong},
  title = {The role of DYNLT3 in breast cancer proliferation, migration, and invasion via epithelial‐to‐mesenchymal transition},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6173}
}
Kostenlos starten →